AXCELON BIOPOLYMERS CORP. ANNOUNCES HEALTH CANADA LICENSE FOR ITS LEAD WOUNDCARE PRODUCT NANODERM©
July 25, 2014
AXCELON ENTERS INTO A CANADIAN 
DISTRIBUTION AGREEMENT WITH THE STEVENS COMPANY FOR NANODERM™ 
March 19, 2015

AXCELON BIOPOLYMERS CORP. ANNOUNCES CLOSING OF PRIVATE PLACEMENT FINANCING IN ITS WOUNDCARE SUBSIDIARY

Toronto, Ontario , November25, 2014. Axcelon Biopolymers Corp. (ABC) announced today that a private
placement financing of $1 Million has been completed in Axcelon Dermacare Inc. (ADI), a subsidiary of
ABC, with an investment from VHealth Scientific Inc. of Toronto. Proceeds from the nonbrokered
private placement will be used primarily for the commercialization of ADI’s lead product Nanoderm™
that recently received Health Canada registration as a Class 2 medical device. Funds will also be used
for development and commercialization of ADI’s other advanced products in the wound-care market.

“We are delighted to have VHealth Scientific Inc. as a shareholder and partner in Axcelon Dermacare Inc.
They bring a wealth of expertise and experience in wound care as well as other medical devices”, said
Dr. Chandra Panchal, Chairman and CEO of ABC and ADI.

“We are very pleased to be able to participate as a partner and an investor. We believe that the
company’s novel product, Nanoderm™, has great potential, both in North America and abroad”, said
Ms. Mei Xu, President of VHealth Scientific Inc.
Terms of the private placement have not been released. VHealth Scientific will be represented
on the Board of Directors of ADI.

Nanoderm™ is a novel biocellulose based nanotechnology that makes it unique in the $2 billion woundcare
market in Canada. As a simple, one-time dressing application, Nanodermtm provides both a suitable
barrier to infections while keeping a desirable moist environment to the wound, allowing gaseous
exchange and pain alleviation. Nanoderm™ is indicated for a variety of treatments including second
degree burns, dermabrasions as well as acute and chronic wounds.

Nanoderm™ is manufactured in Canada by Axcelon’s strategic partner, ZBX Corporation of Toronto
under its ISO 13485 Quality Management System.

About Axcelon Biopolymers Corp.
Axcelon Biopolymers Corp. is a private company developing and commercializing bacterial cellulose
based products for biomedical devices as well as for non-medical applications. The company has several
proprietary assets for development of advanced wound-care products, cardiovascular grafts, tympanic membrane as well as other high value consumer products. With its head office in London, Ontario,
Axcelon maintains key operations in Toronto as well as Montreal

Axcelon Dermacare Inc. is a majority owned subsidiary of Axcelon Biopolymers Corp. and is based in
Toronto, Ontario.
VHealth Scientific Inc. is a Toronto, Ontario based Investment company with a keen focus in the
biomedical industry.
Contact information: Dr. Chandra Panchal, CEO; cpanchal@axcelonbp.com

Tel: 519 878 6157
www.axcelonbp.com
This news release may contain forward-looking statements that reflect the Company’s current expectation regarding
future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited
to the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties related to the regulatory approval
process, and other risks.